Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Trends Pharmacol Sci. 2009 Apr 7;30(5):240–248. doi: 10.1016/j.tips.2009.02.005

Table 2.

Siglec-targeted antibodies in clinical development for treatment of immune cell diseases

Antibody Target Construct Status
Gemtuzumab
ozogamicin
(Mylotarg™)
CD33 Humanized murine IgG
conjugated to calicheamicin
Approved for AML
CMC-544 CD22 IgG4 conjugated to
calecheamicin
Phase II/III for NHL
BL22 CD22 Recombinant Ig-
pseudomonas toxin
conjugate
Phase II for hairy cell leukemia
Epratuzumab CD22 Humanized IgG1 Phase III
HHS Vulnerability Disclosure